Article
Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
The Journal of infectious diseases - 1 May 1995
Staszewski S, Massari F E, Kober A, Göhler R, Durr S, Anderson K W, Schneider C L, Waterbury J A, Bakshi K K, Taylor V I
Abstract excerpt
L-697,661 is a human immunodeficiency virus type 1 (HIV-1)-specific nonnucleoside reverse transcriptase (RT) inhibitor. Its tolerability and activity in combination with zidovudine were evaluated in a 48-week double-blind study. One hundred nineteen zidovudine-naive HIV-1-infected patients with CD4 cell counts of 200-500/mm3 received either combination therapy, L-697,661 alone, or zidovudine alone. Activity was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.